Abstract
This article briefly reviews the mechanisms of action and clinical uses of platelet inhibitor therapy.
Similar content being viewed by others
References
Goldschmidt PJ, Lopes N, Crawford LE. Atherosclerosis and coronary artery disease. In: Michelson AD, ed. Platelets.New York: Academic Press/Elsevier Science, 2002:375-398.
del Zoppo GJ. Ischemic cerebrovascular disease. In: Michelson AD, ed. Platelets. New York: Academic Press/Elsevier Science, 2002:399-425.
Awtry EH, Loscalzo J. Aspirin. In: Michelson AD, ed.Platelets. New York: Academic Press/Elsevier Science, 2002:745-768.
Agah R, Plow EF, Topol EJ. GPIIb-IIIa antagonists.In: Michelson AD, ed. Platelets. New York: Academic Press/Elsevier Science, 2002:769-785.
Curtin R, Cox D, Fitzgerald D. Clopidogrel and ticlopidine.In: Michelson AD, ed. Platelets. New York: Academic Press/Elsevier Science, 2002:787-801.
Eisert WG. Dipyridamole. In: Michelson AD, ed. Platelets.New York: Academic Press/Elsevier Science, 2002:803-815.
Ikeda Y, Sudo T, Kimura Y. Cilostazol. In: Michelson AD, ed. Platelets. New York: Academic Press/Elsevier Science, 2002:817-823.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Michelson, A.D. Platelet Inhibitor Therapy: Mechanisms of Action and Clinical Use. J Thromb Thrombolysis 16, 13–15 (2003). https://doi.org/10.1023/B:THRO.0000014587.43138.93
Issue Date:
DOI: https://doi.org/10.1023/B:THRO.0000014587.43138.93